TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20006356

Group type: EXPERIMENTAL
Intervention: Intraoperative graft patency assessment using indocyanine‐green fluorescent angiography and transit‐time flowmetry (imaging group)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Standard intraoperative management (control group)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Intraoperative graft patency assessment (imaging group)
Number of subjects: 156
Study: 18166349

Group type: EXPERIMENTAL
Intervention: Elective gynecological surgery
Number of subjects: 132

Group type: COMPARATOR
Intervention: Non-surgery controls
Number of subjects: 132
Study: 16463847

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) administration
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transcranial HPI
Number of subjects: 12

Group type: COMPARATOR
Intervention: Doppler sonography (TCD)
Number of subjects: 12
Study: 12750536

Group type: EXPERIMENTAL
Intervention: Undernourished patients
Number of subjects: 3012

Group type: COMPARATOR
Intervention: Normal nutritional status
Number of subjects: 3012
Study: 10343261

Group type: EXPERIMENTAL
Intervention: Intravenous triiodothyronine (0.4 microgram/kg bolus plus 0.1 microgram/kg infusion over 6 hours, n = 81)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo (n = 89)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Intravenous triiodothyronine
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 7594443

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg capsule)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dihydralazine (intravenous infusion at a rate of 1-3 mg/h)
Number of subjects: 20
Study: 1903023

Group type: EXPERIMENTAL
Intervention: Irradiation and hyperthermia (42.5 degrees C, 45‐60 min)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Irradiation alone
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Irradiation and hyperthermia
Number of subjects: 307
Study: 6444323

Group type: EXPERIMENTAL
Intervention: 13cis-retinoic acid
Number of subjects: 238
Study: 30739485

Group type: EXPERIMENTAL
Intervention: High self-esteem
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Longer duration of care
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Less emotional distress
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Shorter duration of care
Number of subjects: 294
Study: 30870236

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release
Number of subjects: 1573

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1573
Study: 28586878

Group type: EXPERIMENTAL
Intervention: Dietary intake of at least 500 mg/d of long-chain omega-3 polyunsaturated fatty acids (LCω3PUFAs)
Number of subjects: 3482

Group type: EXPERIMENTAL
Intervention: Yearly updated LCω3PUFA intake
Number of subjects: 3482
Study: 25698759

Group type: EXPERIMENTAL
Intervention: Alcohol intoxication (0.75 g/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (no alcohol)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Video stimulation (VS)
Number of subjects: 48
Study: 23345623

Group type: EXPERIMENTAL
Intervention: FIR therapy (40 min, three times weekly for one year)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (no FIR therapy)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: FIR therapy
Number of subjects: 280
Study: 20395948

Group type: EXPERIMENTAL
Intervention: LAUNCH (6-month clinic and home-based behavioral intervention)
Number of subjects: 18

Group type: COMPARATOR
Intervention: PC (enhanced standard of care)
Number of subjects: 18
Study: 18663500

Group type: EXPERIMENTAL
Intervention: moxifloxacin 400 mg i.v. once daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: amoxicillin/clavulanic acid 2.2 g i.v. three times daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: moxifloxacin and amoxicillin/clavulanic acid
Number of subjects: 21
Study: 17227570

Group type: EXPERIMENTAL
Intervention: 15 microg/mL IDN-6556 (Organ storage/flush)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 microg/mL IDN-6556 (Organ storage/flush) + 0.5 mg/kg (Recipient)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15 microg/mL IDN-6556 (Organ storage/flush) + 0.5 mg/kg (Recipient)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Organ storage/flush) + Placebo (Recipient)
Number of subjects: 0
Study: 15506589

Group type: EXPERIMENTAL
Intervention: Low-cost multimodal psychosocial intervention
Number of subjects: 187

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 187
Study: 10863139

Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg single dose (Study A)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg single dose (Study B)
Number of subjects: 70
Study: 9174303

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 2.5 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 5.0 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 7.5 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 10.0 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 12.5 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 15.0 microg
Number of subjects: 60
Study: 1335539

Group type: EXPERIMENTAL
Intervention: Captopril (angiotensin-converting enzyme inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 0
Study: 3549877

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 29421001

Group type: EXPERIMENTAL
Intervention: Prehospital ticagrelor treatment
Number of subjects: 1630

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA)
Number of subjects: 1630

Group type: COMPARATOR
Intervention: No thrombus aspiration (no-TA)
Number of subjects: 1630
Study: 27390051

Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome and capecitabine (PC group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Docetaxel, cisplatin, and 5‐fluorouracil (DCF group, control group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 64
Study: 25573705

Group type: EXPERIMENTAL
Intervention: High surgical ligature of spermatic vessels modified Palomo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antegrade sclerotherapy according to Tauber
Number of subjects: 0
Study: 22305833

Group type: EXPERIMENTAL
Intervention: High-concentration oxygen therapy (6 L/min via medium concentration mask)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Titrated oxygen therapy (to achieve oxygen saturation 93%-96%)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: High-concentration oxygen therapy
Number of subjects: 136
Study: 20488431

Group type: EXPERIMENTAL
Intervention: bepotastine besilate ophthalmic solution 1.0%
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: bepotastine besilate ophthalmic solution 1.5%
Number of subjects: 130

Group type: COMPARATOR
Intervention: placebo (0.0%)
Number of subjects: 130
Study: 18515518

Group type: EXPERIMENTAL
Intervention: One E2 spray (1.53 mg E2, 90 microliter)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Two E2 sprays (3.06 mg E2, 180 microliter)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Three E2 sprays (4.59 mg E2, 270 microliter)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Placebo sprays
Number of subjects: 454
Study: 15654152

Group type: EXPERIMENTAL
Intervention: Ventricular pacing mode
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing mode
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pacing for heart failure in elderly patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pacing combined with cardioverter‐defibrillator implantation
Number of subjects: 0
Study: 11920905

Group type: EXPERIMENTAL
Intervention: Fast reporting by amnio-PCR (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard reporting (Group B)
Number of subjects: 60
Study: 9704785

Group type: EXPERIMENTAL
Intervention: 140 mg/dL cutoff value in oral glucose challenge test
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: 142 mg/dL cutoff value in oral glucose challenge test
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: 141 mg/dL cutoff value in oral glucose challenge test
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: 136 mg/dL cutoff value in oral glucose challenge test
Number of subjects: 704
Study: 8527690

Group type: EXPERIMENTAL
Intervention: HI-6 (500 mg) with atropine sulphate (2 mg)
Number of subjects: 24
Study: 1978503

Group type: EXPERIMENTAL
Intervention: D-phenylalanine (4.0 grams orally 30 minutes before acupuncture)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: D-phenylalanine (4.0 grams orally 30 minutes before acupuncture anesthesia)
Number of subjects: 86

Group type: COMPARATOR
Intervention: D-phenylalanine (0.5 grams three times the day before treatment)
Number of subjects: 86
Study: 631733

Group type: EXPERIMENTAL
Intervention: Phenformin 50 mg every 12 hours for 3 days before and during the fasts
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31506859

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy for Posttraumatic Stress Disorder
Number of subjects: 0
Study: 30144887

Group type: EXPERIMENTAL
Intervention: Top-D (Vitamin D3 gel made from proniosomal technology) applied daily on the skin, 1 g containing 5000 IU of vitamin D3
Number of subjects: 550

Group type: COMPARATOR
Intervention: Aloe vera gel applied daily, 1 g
Number of subjects: 550
Study: 26685814

Group type: EXPERIMENTAL
Intervention: HealthKick intervention
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 24585900

Group type: EXPERIMENTAL
Intervention: Modified St. Thomas' Hospital cardioplegic solution (group S)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional glucose-insulin-potassium solution (group G)
Number of subjects: 90
Study: 22732331

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Non-LC phosphorus binders (control)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 13
Study: 20849601

Group type: EXPERIMENTAL
Intervention: Educational programme
Number of subjects: 207

Group type: COMPARATOR
Intervention: Physical training programme
Number of subjects: 207
Study: 17487874

Group type: EXPERIMENTAL
Intervention: Intensive pelvic floor exercises (PFE) starting 7 days after catheter removal for up to 1 year
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (no instructions)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS) at 12 months
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) question at 12 months
Number of subjects: 107
Study: 15843702

Group type: EXPERIMENTAL
Intervention: Benzylpenicillin and flucloxacillin combined
Number of subjects: 81

Group type: COMPARATOR
Intervention: Flucloxacillin only
Number of subjects: 81
Study: 12529796

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (Cr)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 9829449

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 7862844

Group type: COMPARATOR
Intervention: 0.0 g/kg alcohol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.3 g/kg alcohol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.6 g/kg alcohol
Number of subjects: 20
Study: 2816793

Group type: EXPERIMENTAL
Intervention: 51 mmol NaCl/d
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 102 mmol NaCl/d
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (usual diet without supplementation)
Number of subjects: 17
Study: 1104303

Group type: EXPERIMENTAL
Intervention: etofibrate
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: clofibrate
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study: 463982

Group type: EXPERIMENTAL
Intervention: Pelvic plus abdominopelvic irradiation (P + AB)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Pelvic irradiation alone or followed by adjuvant daily chlorambucil therapy
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Chlorambucil added to pelvic irradiation
Number of subjects: 190
Study: 28398129

Group type: EXPERIMENTAL
Intervention: Tai Chi: Moving for Better Balance (12-week program)
Number of subjects: 131
Study: 30283182

Group type: EXPERIMENTAL
Intervention: Lidocaine 2 mg/kg/h with a maximum of 200 mg/h starting at induction of anesthesia until the end of surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Magnesium sulfate 50 mg/kg iv bolus in 100ml saline over 10 min followed by infusion of 15 mg/kg/h until the end of surgery
Number of subjects: 80
Study: 26633571

Group type: EXPERIMENTAL
Intervention: Genomic Grade assay
Number of subjects: 883

Group type: COMPARATOR
Intervention: Histological grade
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: GG equivocal patients
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: GG3 patients
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Ki67
Number of subjects: 883
Study: 25272582

Group type: EXPERIMENTAL
Intervention: Awareness of osteoporosis and its risk factors among subjects with osteoporosis
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dairy product consumption
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fractures reported in the last year
Number of subjects: 150
Study: 22517399

Group type: EXPERIMENTAL
Intervention: Cilengitide 500 mg with standard radiation and temozolomide
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cilengitide 2000 mg with standard radiation and temozolomide
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cilengitide (both doses) with standard radiation and temozolomide
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cilengitide with standard radiation and temozolomide for patients with methylated MGMT status
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cilengitide with standard radiation and temozolomide for patients with unmethylated MGMT status
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cilengitide with standard radiation and temozolomide for patients aged ≤70 years
Number of subjects: 112

Group type: COMPARATOR
Intervention: EORTC trial (historical control)
Number of subjects: 112
Study: 19751434

Group type: EXPERIMENTAL
Intervention: Lactobacilli supplementation
Number of subjects: 1372

Group type: COMPARATOR
Intervention: Standard triple therapy without Lactobacilli
Number of subjects: 1372
Study: 17931323

Group type: EXPERIMENTAL
Intervention: Nurse-led interventions
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nurse-led care
Number of subjects: 22
Study: 15040646

Group type: EXPERIMENTAL
Intervention: Macrolide therapy
Number of subjects: 12032
Study: 12409967

Group type: EXPERIMENTAL
Intervention: Cortisol infusion (0.625, 1.25 and 2.5 microg/kg per min for 10 min each)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cortisol infusion
Number of subjects: 27

Group type: COMPARATOR
Intervention: Glycyrrhetinic acid (GRA; 500 mg orally 2.5 h before the study)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 9809729

Group type: EXPERIMENTAL
Intervention: Glipizide GITS (5 to 20 mg)
Number of subjects: 569
Study: 11256901

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) added peritoneal dialysis (PD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard peritoneal dialysis (PD)
Number of subjects: 40
Study: 2758758

Group type: EXPERIMENTAL
Intervention: 57 mm thermal clearance probe
Number of subjects: 41

Group type: COMPARATOR
Intervention: 18 mm thermal clearance probe
Number of subjects: 41
Study: 1000519

Group type: EXPERIMENTAL
Intervention: Cis-dichlorodiammineplatinum(II) high-dose schedule (30 mg/m2 daily for 3 days every 4 weeks)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cis-dichlorodiammineplatinum(II) low-dose schedule (30 mg/m2 once every 2-3 weeks)
Number of subjects: 34
Study: 29654913

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 599
Study: 27401882

Group type: EXPERIMENTAL
Intervention: Prolonged release oxycodone/naloxone (OXN PR)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 24836758

Group type: EXPERIMENTAL
Intervention: Treatment groups (specific treatments not detailed)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Recruitment, acceptability, and attrition rates
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Roland Morris Disability Questionnaire
Number of subjects: 59
Study: 22402971

Group type: EXPERIMENTAL
Intervention: Restricted fluid regimen (R group)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Standard fluid regimen (S group)
Number of subjects: 179
Study: 20553586

Group type: EXPERIMENTAL
Intervention: Vigileo group (SVV guided fluid optimization)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vigileo group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 18666721

Group type: EXPERIMENTAL
Intervention: 0.5% aqueous gentian violet (GV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hydrogel dressing
Number of subjects: 30
Study: 16439809

Group type: COMPARATOR
Intervention: White petrolatum (glycerin) as positive control
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Products containing dimethicone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Zinc oxide‐based products
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Water‐in‐oil petrolatum‐based product
Number of subjects: 18
Study: 12856481

Group type: EXPERIMENTAL
Intervention: Increased digoxin synthesis with upregulated tryptophan catabolism (increased serotonin, strychnine, nicotine) and downregulated tyrosine catabolism (decreased dopamine, noradrenaline, morphine) in chronic insomnia with right hemispheric dominance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reduced digoxin synthesis with downregulated tryptophan catabolism (decreased serotonin, strychnine, nicotine) and upregulated tyrosine catabolism (increased dopamine, noradrenaline, morphine) in normal sleep patterns with left hemispheric dominance
Number of subjects: 0
Study: 11019348

Group type: EXPERIMENTAL
Intervention: Hospital group (discharged earlier)
Number of subjects: 78
Study: 8973666

Group type: EXPERIMENTAL
Intervention: Transurethral alprostadil (125, 250, 500, and 1000 micrograms)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 1574768

Group type: EXPERIMENTAL
Intervention: Breast preservation
Number of subjects: 1112

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: Tumor-involved margins
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: Transmembrane proteins (EGFR, p-185, p-148, c-myc)
Number of subjects: 1112
Study: 2865009

Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine cream 1%
Number of subjects: 145

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 145

Group type: COMPARATOR
Intervention: Clotrimazole cream 1%
Number of subjects: 145
Study: 30078618

Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study: 26943843

Group type: EXPERIMENTAL
Intervention: Transfusion threshold of 10 g/dl
Number of subjects: 200

Group type: COMPARATOR
Intervention: Transfusion threshold of 7 g/dl
Number of subjects: 200
Study: 24942833

Group type: EXPERIMENTAL
Intervention: Higher NT-proBNP (≥450ng/l)
Number of subjects: 5205
Study: 22401633

Group type: EXPERIMENTAL
Intervention: Immunoxel (Dzherelo) administered once-daily along with TB drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunoxel (Dzherelo)
Number of subjects: 0
Study: 20590480

Group type: EXPERIMENTAL
Intervention: Bacopa monnieri (BacoMind(TM)) 300 mg/day
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 18334874

Group type: EXPERIMENTAL
Intervention: Real-time PCR for H. pylori detection
Number of subjects: 103

Group type: COMPARATOR
Intervention: Urea breath test (UBT)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Serological testing
Number of subjects: 103

Group type: COMPARATOR
Intervention: Histology
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Real-time PCR ureaseA/beta-globin ratio
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Real-time PCR for bacterial density
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Real-time PCR VacA s1
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: CagA results
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Genomic profiles (VAC/GAC)
Number of subjects: 103
Study: 15819764

Group type: EXPERIMENTAL
Intervention: 0.5 mg intrathecal morphine
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.2 mg intrathecal morphine
Number of subjects: 70
Study: 12439518

Group type: EXPERIMENTAL
Intervention: Intermediate bacterial vaginosis
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Frank bacterial vaginosis
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Any detectable defensin
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Presence of leukocytes in vaginal fluids
Number of subjects: 749
Study: 10506854

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 30
Study: 8947397

Group type: EXPERIMENTAL
Intervention: Tourniquet use (Group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No tourniquet (Group II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Group I and Group II)
Number of subjects: 40
Study: 1911676

Group type: EXPERIMENTAL
Intervention: 4.0 ml of 2% lignocaine containing 1:80000 adrenaline
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4.0 ml of 2% lignocaine (adrenaline-free)
Number of subjects: 20